Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia.

Maetzler W, Tian Y, Baur SM, Gauger T, Odoj B, Schmid B, Schulte C, Deuschle C, Heck S, Apel A, Melms A, Gasser T, Berg D.

PLoS One. 2012;7(10):e48042. doi: 10.1371/journal.pone.0048042. Epub 2012 Oct 25.

2.

Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid-β pathway.

Maetzler W, Stapf AK, Schulte C, Hauser AK, Lerche S, Wurster I, Schleicher E, Melms A, Berg D.

J Alzheimers Dis. 2011;27(1):119-26. doi: 10.3233/JAD-2011-110587.

PMID:
21765209
3.

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.

Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG.

Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X. Erratum in: Lancet Neurol. 2011 Apr;10(4):297.

PMID:
21317042
4.

Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.

Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P.

Biol Psychiatry. 2008 Nov 15;64(10):850-5. doi: 10.1016/j.biopsych.2008.02.016. Epub 2008 Apr 8.

PMID:
18395699
5.

Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.

Mollenhauer B, Steinacker P, Bahn E, Bibl M, Brechlin P, Schlossmacher MG, Locascio JJ, Wiltfang J, Kretzschmar HA, Poser S, Trenkwalder C, Otto M.

Neurodegener Dis. 2007;4(5):366-75. Epub 2007 Jul 6.

PMID:
17622779
6.

Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-β42 levels in Lewy body disease.

Maetzler W, Stoycheva V, Schmid B, Schulte C, Hauser AK, Brockmann K, Melms A, Gasser T, Berg D.

J Alzheimers Dis. 2010;22(3):933-8. doi: 10.3233/JAD-2010-101197.

PMID:
20858953
7.

CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia.

Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Rüther E, Kornhuber J, Otto M, Wiltfang J.

Brain. 2006 May;129(Pt 5):1177-87. Epub 2006 Apr 6.

8.

High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia.

Vijayaraghavan S, Maetzler W, Reimold M, Lithner CU, Liepelt-Scarfone I, Berg D, Darreh-Shori T.

Alzheimers Dement. 2014 Sep;10(5):530-540.e1. doi: 10.1016/j.jalz.2013.03.010. Epub 2013 Aug 24.

PMID:
23978325
9.

Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors.

Schultz K, Nilsson K, Nielsen JE, Lindquist SG, Hjermind LE, Andersen BB, Wallin A, Nilsson C, Petersén A.

Eur J Neurol. 2010 Mar;17(3):456-60. doi: 10.1111/j.1468-1331.2009.02841.x. Epub 2009 Nov 17.

PMID:
19922456
10.

Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias.

Maetzler W, Berg D, Synofzik M, Brockmann K, Godau J, Melms A, Gasser T, Hörnig S, Langkamp M.

J Alzheimers Dis. 2011;26(1):171-9. doi: 10.3233/JAD-2011-110221.

PMID:
21593566
11.

Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies.

Nielsen HM, Hall S, Surova Y, Nägga K, Nilsson C, Londos E, Minthon L, Hansson O, Wennström M.

J Alzheimers Dis. 2014;40(2):343-50. doi: 10.3233/JAD-132246.

PMID:
24448788
12.

Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases.

Maetzler W, Schmid SP, Wurster I, Liepelt I, Gaenslen A, Gasser T, Berg D.

Mov Disord. 2011 Jan;26(1):176-81. doi: 10.1002/mds.23358. Epub 2010 Sep 14.

PMID:
20842692
13.

Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia.

Gloeckner SF, Meyne F, Wagner F, Heinemann U, Krasnianski A, Meissner B, Zerr I.

J Alzheimers Dis. 2008 May;14(1):17-25.

PMID:
18525124
14.

Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease.

Compta Y, Valente T, Saura J, Segura B, Iranzo Á, Serradell M, Junqué C, Tolosa E, Valldeoriola F, Muñoz E, Santamaria J, Cámara A, Fernández M, Fortea J, Buongiorno M, Molinuevo JL, Bargalló N, Martí MJ.

J Neurol. 2015 Feb;262(2):294-306. doi: 10.1007/s00415-014-7560-z. Epub 2014 Nov 8.

PMID:
25380583
15.

Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy.

Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Boström F, Hansson O, Nielsen HM.

PLoS One. 2013;8(1):e53250. doi: 10.1371/journal.pone.0053250. Epub 2013 Jan 8.

16.

Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum.

Sierra M, Gelpi E, Martí MJ, Compta Y.

Neuropathol Appl Neurobiol. 2016 Aug;42(5):451-62. doi: 10.1111/nan.12308. Epub 2016 Apr 1.

PMID:
26810462
17.

Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.

Kaerst L, Kuhlmann A, Wedekind D, Stoeck K, Lange P, Zerr I.

J Alzheimers Dis. 2014;38(1):63-73. doi: 10.3233/JAD-130995.

PMID:
23948928
18.

CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD.

Stefani A, Brusa L, Olivola E, Pierantozzi M, Martorana A.

J Neural Transm (Vienna). 2012 Jul;119(7):861-75. doi: 10.1007/s00702-012-0820-0. Epub 2012 May 24. Review.

PMID:
22622365
19.

GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia.

Maetzler W, Deleersnijder W, Hanssens V, Bernard A, Brockmann K, Marquetand J, Wurster I, Rattay TW, Roncoroni L, Schaeffer E, Lerche S, Apel A, Deuschle C, Berg D.

PLoS One. 2016 Mar 3;11(3):e0149349. doi: 10.1371/journal.pone.0149349. eCollection 2016.

20.

Cortical Lewy bodies and Aβ burden are associated with prevalence and timing of dementia in Lewy body diseases.

Ruffmann C, Calboli FC, Bravi I, Gveric D, Curry LK, de Smith A, Pavlou S, Buxton JL, Blakemore AI, Takousis P, Molloy S, Piccini P, Dexter DT, Roncaroli F, Gentleman SM, Middleton LT.

Neuropathol Appl Neurobiol. 2016 Aug;42(5):436-50. doi: 10.1111/nan.12294. Epub 2015 Dec 2.

PMID:
26527105

Supplemental Content

Support Center